

REMARKS

III. Specification:

The amendment to the specification is made merely to add a sequence identifier to the sequence described in Figure 2A, and does not add or constitute new matter. Moreover, the sequence described in Figure 2A (SEQ ID NO:1) is the same sequence described in Figure 1 (the FPR-RS4 gene described in the instant application and disclosed in SEQ ID NO:1). Support for the amendment can be found throughout the specification, claims and drawings as originally filed, and specifically can be found at page 9, lines 1-4, of the specification and in Figure 2A as originally filed.

III. Drawings/Sequence Compliance:

The Examiner has asserted that the instant application fails to comply with the requirements of 37 CFR 1.821 through 1.825, because the sequence disclosed in Figure 2A allegedly was not described in the sequence listing submitted with the application as filed. The Applicant contends that the sequence described in Figure 2A is identical to the sequence described as SEQ ID NO:1 in Figure 1 and in the original sequence listing, and thus submit that the sequence has been included in the sequence listing filed.

The Applicant has amended Figure 2A to include the inadvertently omitted sequence identifier. New Figure 2A with the amendment incorporated therein is attached herewith. The amendment to Figure 2A is merely the addition of the sequence identifier at the end of the sequence disclosed therein (SEQ ID NO:1). The amendment does not add or constitute new matter, and is completely supported by the application as originally filed. Specifically, support may be found at page 10, lines 24-31, of the specification, and in originally filed Figures 1 and 2A. As the sequence described in Figure 2A, to which the Examiner refers in the instant Office Action, is included in the sequence listing as previously filed (SEQ ID NO:1), and in light of the amendment to Figure 2A to more clearly identify the sequence as SEQ ID NO:1, the Applicant believes he is now in full compliance with the requirements of 37 CFR 1.821 through 1.825.

The Applicant contends that Sequence Listing submitted on April 2, 2002, in computer readable format (CRF) and paper, contains all sequences disclosed in the application. Therefore, the Applicant believes that a substitute Sequence Listing in CRF is not required. Moreover, the content of the paper and computer readable copies of the Sequence Listing submitted on April 2, 2002 are identical. The sequence listing submitted in this application merely presents nucleotide

and/or amino acid sequences that appeared in the application as originally filed in accordance with 37 C.F.R. §1.821-1.825, thus no new matter has been introduced into the application.

III. Requirement for Restriction:

In response to the Examiner's requirement for restriction in the instant Office Action, the Applicant elects, without traverse, Group II (claims 3-9 and 14-22 and 34-37), drawn to a cell having a disruption in an FPR-RS4 gene, and transgenic animals having a disruption in an FPR-RS4 gene.

The Applicant respectfully requests entry and consideration of the foregoing amendments and remarks. Upon entry of the amendments, claims 3-9 and 14-22 and 34-37 are pending in the instant application.

Respectfully submitted,

Date: 8/12/03

Kelly L. Quast

Kelly L. Quast, Reg. No. 52,141
Deltagen, Inc.
700 Bay Road
Redwood City, CA 94063
(650) 569-5100

Enclosures

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence and its listed enclosures is being deposited with the United States Postal Service as First Class Mail, postage paid, in an envelope addressed to: Commissioner for Patents, Alexandria, VA, Mail Stop Non- Fee Amendment/OIPE on August 12, 2003.

Name: **Don Mixon**

Signed: Don Mixon

Date: 8/12/03